Biopharma Quarterly Dealmaking Statistics, Q3 2019
A Look At Financing, M&A And Alliance Activity July-September 2019
During Q3, biopharma company fundraising reached $13.3bn, mostly from follow-on public offerings, which again made up the most of those dollars. Despite numerous deals valued at $100m+, M&A activity was the lowest of the year. Many of the biggest partnership deals were centered around the inflammation/immune area.
You may also be interested in...
The Swedish group has got hold of the ITP and CLD drug Doptelet, widening its hematology business beyond hemophilia.
Shares of China’s Shanghai Henlius Biotech will debut on the Hong Kong stock exchange later this week after the company collected $410m in an IPO that was priced at the bottom end of the targeted range.
Deborah Dunsire tells Scrip that buying Alder offers Lundbeck a blockbuster prevention treatment for severe migraine patients, and helps rebuild Danish group’s prospects.